
    
      This was an open-label study of 60 weeks duration in elderly patients (â‰¥65 years) with
      primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in
      study NK-104-306 and who met the inclusion/exclusion criteria. Patients who qualified started
      open-label treatment with pitavastatin 2 mg QD. The dose of pitavastatin could be increased
      to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain
      their LDL-C target.
    
  